Systemic mastocytosis: current classification and novel therapeutic options

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Systemic mast cell disease (SMC) is marked by uncontrolled mast cell proliferation and mediator release.
• Activating mutations in the c-KIT receptor tyrosine kinase drive aberrant signaling in most SMC patients.
• The common c-KIT D816V mutation confers resistance to imatinib therapy.

Observation:

• Imatinib, a targeted therapy, is largely ineffective against the prevalent c-KIT D816V mutation in systemic mast cell disease.
• Mast cell biology has seen significant advancements in understanding growth regulation over the past two decades.

Findings:

• Novel therapeutic strategies targeting mast cells with the c-KIT D816V mutation have demonstrated efficacy in in vitro studies.
• These new approaches aim to overcome imatinib resistance.

Implications:

• Developing effective treatments for systemic mast cell disease, particularly forms driven by the c-KIT D816V mutation, remains a critical unmet need.
• These findings suggest potential for new targeted therapies in treatment-refractory systemic mast cell disease.
• Further research into novel inhibitors could lead to improved patient outcomes.